Cingulate Announces Positive Top-Line Results from ADHD Study

 Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food

CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced positive top-line results from the CTx-1301-003 study assessing the effect of food on absorption of its lead candidate CTx-1301. CTx-1301 is a novel, investigational, trimodal, extended-release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD).

The trial demonstrated that CTx-1301 can be taken with or without food. Multiple pharmacokinetic (PK) measurements were taken and adverse events were consistent with previous findings and indicate a favorable tolerability profile.

https://www.biospace.com/article/releases/cingulate-announces-positive-top-line-results-from-fed-fast-study-of-lead-asset-ctx-1301-for-adhd/